NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Combined Biomarker Testing for Early Heart Disease Risk Identification
TL;DR
Combining three biomarker tests provides a competitive edge in identifying individuals with triple the heart attack risk for earlier preventive interventions.
The study systematically analyzed lipoprotein(a), remnant cholesterol, and hsCRP biomarkers across 300,000 participants over 15 years to establish cumulative risk patterns.
This combined biomarker approach helps healthcare professionals provide earlier personalized care, potentially preventing heart attacks and saving lives through targeted prevention.
Three simple blood tests working together reveal hidden heart attack risks by measuring genetic factors, cholesterol metabolism, and inflammation simultaneously.
Found this article helpful?
Share it with your network and spread the knowledge!
Adults with elevated levels of all three biomarkers—lipoprotein(a), remnant cholesterol, and high-sensitivity C-reactive protein—had nearly triple the risk of heart attack compared to those with normal levels.
The three biomarkers are lipoprotein(a) (Lp(a)), remnant cholesterol, and high-sensitivity C-reactive protein (hsCRP), which measure different pathways to cardiovascular disease including genetics, cholesterol metabolism, and inflammation.
Combining the results helps healthcare professionals identify individuals with the highest heart attack risk more quickly and may guide more personalized prevention strategies, as each biomarker alone shows only modest risk increases.
People with one elevated biomarker had a 45% increased risk, those with two elevated biomarkers had double the risk, and those with all three elevated had nearly triple the risk of heart attack.
Lipoprotein(a) is largely inherited cholesterol that causes plaque buildup; remnant cholesterol refers to harmful fat particles standard tests miss; and hsCRP measures inflammation that may indicate artery damage risk.
The research was led by Dr. Richard Kazibwe from Wake Forest University School of Medicine and will be presented at the American Heart Association's Scientific Sessions 2025 in New Orleans.
This is a preliminary research abstract presented at a scientific meeting; the findings are not yet peer-reviewed and are considered preliminary until published in a peer-reviewed scientific journal.
Researchers analyzed health data from over 300,000 participants in the UK Biobank who were free of heart disease initially, tracking heart attack rates over a median follow-up of 15 years.
The embargo lifts at 4 a.m. CT/5 a.m. ET on Monday, November 3, 2025, and the findings will be presented at the Scientific Sessions from November 7-10, 2025.
These findings suggest that combined biomarker testing could help identify high heart disease risk earlier, but the research is preliminary and not yet peer-reviewed, so consult healthcare providers for personalized medical advice.
Curated from NewMediaWire
